Oisin Biotechnologies

Oisín Biotechnologies is a private, preclinical-stage biotech pioneering genetic medicines for aging-related conditions. Its core innovation is the Fusogenix™ PLV, a novel non-viral delivery system designed to overcome the limitations of viral vectors by enabling targeted delivery to tissues beyond the liver and allowing for repeat administration. The company has built a pipeline targeting key hallmarks of aging, including muscle loss (frailty), adipose tissue, and senescent cells, positioning it in the rapidly growing longevity and geroscience markets. With an experienced leadership team and a platform with potential broad applicability, Oisín aims to develop transformative therapies for diseases of aging.

Fusogenix™ Proteo-Lipid Vehicle (PLV), a non-viral delivery platform for DNA and RNA payloads enabling extrahepatic biodistribution and repeat dosing.

Oisín competes in the senolytics space with companies like Unity Biotechnology and Cleara Biotech, in muscle regeneration with others, and broadly in non-viral gene delivery with numerous biotechs and large pharma. Its differentiation hinges on the unique biodistribution and repeat-dosing profile of its Fusogenix™ PLV technology.